Sunday, January 11, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Tilray Files Prospectus Supplement for Resale of 124 Million Shares of Common Stock

Elaine Mendonca by Elaine Mendonca
January 10, 2024
in Breaking News
0
0
SHARES
3
VIEWS
Share on FacebookShare on Twitter

Tilray, a leading player in the pharmaceutical and cannabis industry, has recently taken a significant step towards expanding its market presence. In a move that highlights its commitment to transparency and compliance, the company has filed a prospectus supplement on January 10, 2024. This filing aims to register the resale of an impressive 12.4 million shares of common stock by a selling stockholder.

The prospectus supplement, which can be accessed on the U.S. Securities and Exchange Commission (SEC) website, offers a comprehensive overview of the offering, shedding light on the company’s financial condition and other pertinent details. It serves as a valuable resource for investors and stakeholders seeking a deeper understanding of Tilray’s current position and future prospects.

To access the complete filing and delve into the intricate details of this exciting development, interested parties are encouraged to visit the SEC website. This filing underscores Tilray’s dedication to maintaining transparency and providing its stakeholders with the necessary information to make informed decisions.

[bs_slider_forecast ticker=”TLRY”]

Analyzing Tilray Inc.s Stock Price Drop on January 10, 2024: Factors and Implications

On January 10, 2024, Tilray Inc. (TLRY) experienced a significant drop in its stock price. The stock closed at $2.11, marking a decrease of $0.23 since the previous market close, translating to a decline of 9.83% in TLRY shares. TLRY was trading in the middle of its 52-week range, suggesting that its price was neither at its highest nor lowest point within the past year. Additionally, the stock was below its 200-day simple moving average, indicating a potential bearish trend. The drop in TLRY’s stock price on January 10, 2024, may have been influenced by various factors, and investors and analysts would likely examine these factors to gain a better understanding of the reasons behind the drop and to assess the potential implications for the company’s future performance. It is important to note that stock prices can be volatile, and daily fluctuations are a common occurrence. Therefore, a single day’s performance should not be taken as a definitive indicator of a company’s overall financial health or long-term prospects. Investors are advised to consider a range of factors, including historical performance, industry trends, and company fundamentals, when making investment decisions.

[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”TLRY” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]

TLRY Stock Performance: Total Revenue and Net Income Analysis on January 10, 2024

TLRY Stock Performance on January 10, 2024:

– Total revenue for Tilray Inc. (TLRY) in the past year was $627.12 million.
– Total revenue in the previous quarter was $193.77 million, showing a flat performance since last year.
– There was a 9.51% increase in total revenue since the previous quarter.
– Net income for the past year was -$1.45 billion, indicating a significant loss.
– Net income in the second quarter improved to -$49.01 million, showing a 31.48% increase since the previous quarter.
– Net income decreased by 204.67% since the previous year.
– Earnings per share (EPS) for the past year was -$2.35, indicating a loss per share.
– EPS in the second quarter improved to -$0.07, showing a 35.17% increase since the previous quarter.
– EPS decreased by 137.24% since the previous year.
– Tilray’s financial performance has been mixed, with positive growth in total revenue and net income since the previous quarter, but significant challenges indicated by the decrease in net income and EPS since the previous year.
– The cannabis industry, in which Tilray operates, has faced regulatory hurdles and market volatility in recent years, which can impact financial performance.
– Investors and analysts will closely monitor Tilray’s future financial reports to assess its ability to overcome challenges and achieve sustainable growth.
– Thorough research and consideration of various factors, including industry trends, competitive landscape, and management strategies, are important when evaluating stock performance and making investment decisions.

Tags: TLRY
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post

AZZ Inc Reports Impressive ThirdQuarter Results

COST stock news

MKS Instruments A Promising Outlook for 2024

COST stock news

Analyst Reiterates Positive Stance on SMART Global Holdings with Increased Price Target

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recommended

Chatham Lodging Stock

Chatham Lodging Trust Faces Significant Q3 Headwinds

1 month ago
SNDR stock news

Truist Securities Analyst Maintains Hold Rating on Woodward NASDAQWWD with Increased Price Target

2 years ago
Lennox Stock

Lennox International: Navigating Headwinds with Strategic Acquisitions and Shareholder Returns

4 weeks ago
C3.ai Stock

C3.ai Faces Critical Juncture as Strategic Options Are Explored

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Assessing 21Vianet’s Impressive Yet Uncertain Stock Surge

Freshworks Shares Gain on Strategic Pricing and Acquisition Moves

A Domestic Focus Fuels Record Rally for Metals and Mining ETF

Sana Biotechnology Shares Gain on Analyst Upgrade and Upcoming Catalyst

Silver Nears Historic Peak Amid Rate Cut Speculation and Supply Concerns

IBM’s Strategic Pivot Gains Favor with Market Analysts

Trending

Pfizer Stock
Analysis

Pfizer’s Strategic Pivot Gains Momentum with Clinical and Deal Success

by Andreas Sommer
January 11, 2026
0

Pfizer is demonstrating tangible progress in its strategic shift away from reliance on COVID-19 products. A combination...

BYD Stock

BYD Surpasses Tesla to Claim Global EV Sales Crown

January 11, 2026
SpaceX Stock

A Trio of Catalysts Propels SpaceX Forward

January 10, 2026
21Vianet Stock

Assessing 21Vianet’s Impressive Yet Uncertain Stock Surge

January 10, 2026
Freshworks Stock

Freshworks Shares Gain on Strategic Pricing and Acquisition Moves

January 10, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Pfizer’s Strategic Pivot Gains Momentum with Clinical and Deal Success
  • BYD Surpasses Tesla to Claim Global EV Sales Crown
  • A Trio of Catalysts Propels SpaceX Forward

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com